CY1112101T1 - Νευροτροφικοι παραγοντες - Google Patents
Νευροτροφικοι παραγοντεςInfo
- Publication number
- CY1112101T1 CY1112101T1 CY20111101173T CY111101173T CY1112101T1 CY 1112101 T1 CY1112101 T1 CY 1112101T1 CY 20111101173 T CY20111101173 T CY 20111101173T CY 111101173 T CY111101173 T CY 111101173T CY 1112101 T1 CY1112101 T1 CY 1112101T1
- Authority
- CY
- Cyprus
- Prior art keywords
- neuroblast
- polypeptides
- neurotrophic factors
- methods
- binding
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract 2
- 102000007072 Nerve Growth Factors Human genes 0.000 title abstract 2
- 239000003900 neurotrophic factor Substances 0.000 title 1
- 210000003757 neuroblast Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000010276 construction Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Η εφεύρεση αφορά πολυπεπτίδια του νευροτροφικού παράγοντα νευροβλαστίνη, νουκλεϊνικά οξέα που κωδικοποιούν πολυπεπτίδια νευροβλαστίνης και αντισώματα που συνδέουν ειδικώς προς πολυπεπτίδια νευροβλαστίνης, καθώς επίσης μεθόδους κατασκευής και μεθόδους χρήσης αυτών.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199800904 | 1998-07-06 | ||
US9222998P | 1998-07-09 | 1998-07-09 | |
DKPA199801048 | 1998-08-19 | ||
US9777498P | 1998-08-25 | 1998-08-25 | |
DKPA199801265 | 1998-10-06 | ||
US10390898P | 1998-10-13 | 1998-10-13 | |
US09/347,613 US6593133B1 (en) | 1998-07-06 | 1999-07-02 | Neurotrophic factors |
EP99931023A EP1095140B1 (en) | 1998-07-06 | 1999-07-05 | Neurotrophic factors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112101T1 true CY1112101T1 (el) | 2015-11-04 |
Family
ID=27561795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111101173T CY1112101T1 (el) | 1998-07-06 | 2011-11-29 | Νευροτροφικοι παραγοντες |
Country Status (18)
Country | Link |
---|---|
US (6) | US6593133B1 (el) |
EP (2) | EP1095140B1 (el) |
JP (5) | JP2002519061A (el) |
KR (1) | KR100743376B1 (el) |
AT (1) | ATE522609T1 (el) |
AU (1) | AU755114B2 (el) |
CA (1) | CA2336218C (el) |
CY (1) | CY1112101T1 (el) |
DK (1) | DK1095140T3 (el) |
EE (1) | EE05590B1 (el) |
ES (1) | ES2373173T3 (el) |
HU (1) | HU227870B1 (el) |
IS (1) | IS2835B (el) |
NZ (1) | NZ508994A (el) |
PT (1) | PT1095140E (el) |
SI (1) | SI1095140T1 (el) |
TR (1) | TR200100056T2 (el) |
WO (1) | WO2000001815A2 (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US7067473B1 (en) * | 1998-07-14 | 2006-06-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
DE69933771T2 (de) * | 1998-07-14 | 2007-09-13 | Janssen Pharmaceutica N.V. | Neurotrophischer wachstumsfaktor |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
AU3755900A (en) * | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
EP1867719A3 (en) * | 1999-06-02 | 2008-03-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
MXPA03005721A (es) * | 2000-12-22 | 2004-04-21 | Genentech Inc | Uso novedoso de artemina, un miembro de la familia de ligandos gdnf. |
EE05537B1 (et) * | 2001-02-01 | 2012-04-16 | Biogen, Inc. | Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks |
US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
ATE526982T1 (de) * | 2001-03-28 | 2011-10-15 | Biogen Idec Inc | Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen |
US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
WO2004005487A2 (en) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
SI1594436T1 (sl) * | 2003-01-31 | 2011-01-31 | Biogen Idec Inc | Mutirani neoblastin |
EP1618179B1 (en) * | 2003-04-18 | 2014-05-07 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
EP1636260B1 (en) | 2003-06-10 | 2009-02-18 | Nsgene A/S | Improved secretion of neublastin |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
CN101043899B (zh) * | 2004-08-19 | 2011-03-30 | 比奥根艾迪克Ma公司 | 重折叠转化型生长因子beta家族蛋白 |
MX2007002029A (es) * | 2004-08-19 | 2007-03-28 | Biogen Idec Inc | Variantes de neublastina. |
US8138148B2 (en) | 2005-08-16 | 2012-03-20 | Copenhagen University | GDNF derived peptides |
WO2007042040A2 (en) * | 2005-10-11 | 2007-04-19 | Ns Gene A/S | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
ES2450065T3 (es) * | 2006-03-01 | 2014-03-21 | Biogen Idec Ma Inc. | Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF |
TWI445544B (zh) * | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | 增進血管形成之組合物及方法 |
CA2691166A1 (en) * | 2007-06-27 | 2008-12-31 | Liu Dongxu | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
EP2968462B1 (en) | 2013-03-15 | 2020-12-23 | The Jackson Laboratory | Methods for promoting wound healing and hair growth |
RU2696481C2 (ru) | 2013-10-14 | 2019-08-02 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd |
US10000741B2 (en) | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
US20180264081A1 (en) * | 2015-01-18 | 2018-09-20 | Gloriana Therapeutics Sarl | Therapeutic protein formulations |
BR112017018846A2 (pt) | 2015-03-02 | 2018-07-31 | Adverum Biotechnologies, Inc. | composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos. |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
ES2107537T3 (es) | 1991-04-25 | 1997-12-01 | Univ Brown Res Found | Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados. |
EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
ATE359842T1 (de) | 1991-07-02 | 2007-05-15 | Nektar Therapeutics | Abgabevorrichtung für nebelförmige medikamente |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
EP0610254B1 (en) | 1991-09-20 | 2004-09-01 | Amgen Inc. | Glial derived neurotrophic factor |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5284350A (en) * | 1992-05-22 | 1994-02-08 | Medical Composite Technology | Foldable wheelchair and side frame assembly |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
PT679088E (pt) | 1992-09-29 | 2002-12-31 | Inhale Therapeutic Syst | Administracao pulmonar de fragmentos activos de hormona paratiroide |
CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
ATE218893T1 (de) | 1993-08-12 | 2002-06-15 | Neurotech Sa | Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten |
DE4339605A1 (de) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden |
US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US6299895B1 (en) * | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6878544B2 (en) * | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
ATE335003T1 (de) | 1996-05-08 | 2006-08-15 | Biogen Idec Inc | Ret-ligand 3 (retl3), um neurales und renales wachstum zu stimulieren |
US5754524A (en) | 1996-08-30 | 1998-05-19 | Wark; Barry J. | Computerized method and system for analysis of an electrophoresis gel test |
KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
US20020192209A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
DE69933771T2 (de) | 1998-07-14 | 2007-09-13 | Janssen Pharmaceutica N.V. | Neurotrophischer wachstumsfaktor |
JP2003524381A (ja) * | 1998-09-22 | 2003-08-19 | ユニヴァーシティ オブ メリーランド,ボルチモア | システインノット成長因子ミュータント |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
DK1607402T3 (da) * | 1999-03-08 | 2007-04-16 | Genentech Inc | Sammensætninger og fremgangsmåder til tumorbehandling |
US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
ES2287020T3 (es) * | 1999-06-02 | 2007-12-16 | Genentech, Inc. | Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas. |
JP2001329126A (ja) | 2000-05-22 | 2001-11-27 | Bridgestone Corp | 硬化性組成物 |
DE60138204D1 (de) * | 2000-09-12 | 2009-05-14 | Jfe Steel Corp | Ultra hochfestes kaltgewalztes stahlblech und sein herstellungsverfahren |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
US7598059B2 (en) * | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
-
1999
- 1999-07-02 US US09/347,613 patent/US6593133B1/en not_active Expired - Lifetime
- 1999-07-05 EP EP99931023A patent/EP1095140B1/en not_active Expired - Lifetime
- 1999-07-05 AT AT99931023T patent/ATE522609T1/de active
- 1999-07-05 CA CA2336218A patent/CA2336218C/en not_active Expired - Fee Related
- 1999-07-05 AU AU47693/99A patent/AU755114B2/en not_active Ceased
- 1999-07-05 WO PCT/DK1999/000384 patent/WO2000001815A2/en active IP Right Grant
- 1999-07-05 ES ES99931023T patent/ES2373173T3/es not_active Expired - Lifetime
- 1999-07-05 SI SI9931062T patent/SI1095140T1/sl unknown
- 1999-07-05 KR KR1020017000184A patent/KR100743376B1/ko not_active IP Right Cessation
- 1999-07-05 PT PT99931023T patent/PT1095140E/pt unknown
- 1999-07-05 DK DK99931023.8T patent/DK1095140T3/da active
- 1999-07-05 EP EP10181304A patent/EP2290079A3/en not_active Withdrawn
- 1999-07-05 TR TR2001/00056T patent/TR200100056T2/xx unknown
- 1999-07-05 JP JP2000558205A patent/JP2002519061A/ja active Pending
- 1999-07-05 NZ NZ508994A patent/NZ508994A/en not_active IP Right Cessation
- 1999-07-05 EE EEP200100008A patent/EE05590B1/xx not_active IP Right Cessation
- 1999-07-05 HU HU0103758A patent/HU227870B1/hu not_active IP Right Cessation
-
2000
- 2000-09-15 US US09/662,183 patent/US6734284B1/en not_active Expired - Lifetime
- 2000-12-14 IS IS5769A patent/IS2835B/is unknown
-
2004
- 2004-03-22 US US10/806,793 patent/US20040230043A1/en not_active Abandoned
-
2005
- 2005-06-01 JP JP2005161155A patent/JP2005341968A/ja not_active Withdrawn
- 2005-11-10 JP JP2005326745A patent/JP2006122053A/ja not_active Withdrawn
-
2007
- 2007-04-27 JP JP2007120282A patent/JP2007252381A/ja not_active Withdrawn
- 2007-10-31 US US11/932,744 patent/US20080227703A1/en not_active Abandoned
- 2007-11-28 JP JP2007307603A patent/JP2008133282A/ja active Pending
-
2009
- 2009-10-27 US US12/606,602 patent/US20100234293A1/en not_active Abandoned
-
2011
- 2011-04-11 US US13/084,267 patent/US20120252726A1/en not_active Abandoned
- 2011-11-29 CY CY20111101173T patent/CY1112101T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112101T1 (el) | Νευροτροφικοι παραγοντες | |
CY1111750T1 (el) | Νευροτροφικοι παραγοντες | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
DK1482041T3 (da) | NL6-TIE-receptor-tyrosinkinase-ligand-homolog | |
ATE544776T1 (de) | Chimäre dna-bindeproteine | |
ATE411082T1 (de) | Neue verwendung von kurzkettigen carbonsäuren | |
PT1015585E (pt) | Homologos de ligandos de tie | |
ATE394484T1 (de) | Smad 6 und dessen anwendungen | |
DE69738454D1 (de) | Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden | |
DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
SE9602822D0 (sv) | New receptor | |
AR022150A1 (es) | Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados | |
DK0939769T3 (da) | Vertebrat-Smoothened-proteiner | |
PE20399A1 (es) | Muteina ob | |
DK1005532T3 (da) | Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf | |
EA200100110A1 (ru) | Нейротрофические факторы | |
DE59813125D1 (de) | Srcr domäne-enthaltendes protein | |
DE69535039D1 (de) | Cytoplasmische tyrosin kinase | |
WO2001021794A3 (en) | Smad associating polypeptides |